Innovent Biologics

1801.HKPhase 3

Suzhou, ChinaFounded 2011innoventbio.com

Innovent Biologics is one of China's premier biotechnology companies, established in 2011 and publicly traded on the Hong Kong Stock Exchange. The company specializes in developing innovative biologics for oncology, autoimmune, and metabolic diseases, with a strong focus on monoclonal antibodies and bispecific antibodies. Innovent has successfully commercialized multiple products in China and has strategic partnerships with global pharmaceutical companies including Eli Lilly and Roche.

Market Cap

$17.8B

Founded

2011

Employees

1,000-2,000

Focus

Biotech

1801.HK · Stock Price

USD 81.05+46.85 (+136.99%)

Historical price data

AI Company Overview

Technology Platform

Comprehensive biotechnology platform focused on monoclonal antibodies, bispecific antibodies, and biosimilar development with integrated discovery, development, and manufacturing capabilities.

Pipeline Snapshot

229

229 drugs in pipeline, 42 in Phase 3

Drug	Indication	Stage
Teprotumumab N01 + Methylprednisolone	Thyroid Eye Disease	Approved
Taxane and Carboplatin + Short-term Sintilimab	Triple-negative Breast Cancer	Approved
Sintilimab + Cisplatin + Paclitaxel + Fluorouracil + Placebo	Esophageal Squamous Cell Carcinoma	Phase 3
Sintilimab + Gemcitabine + Cisplatin + Placebo + Carboplatin	Squamous NSCLC	Phase 3
IBI112 + placebo /IBI112 + IBI112	Psoriasis	Phase 3

Funding History

Total raised: $768M

IPO$483MUndisclosedOct 31, 2018

Series C$160MCapital GroupJun 15, 2016

Series B$100MHillhouse CapitalJun 15, 2015

Series A$25MFidelity InvestmentsJun 15, 2012

Opportunities

Significant opportunities exist for international expansion, particularly in emerging markets, and continued pipeline advancement with multiple programs in development.

The company is well-positioned to capitalize on China's growing biotechnology market and increasing demand for innovative therapies.

Risk Factors

Key risks include intense competition from both domestic and international players, regulatory challenges in new markets, and dependence on successful clinical trial outcomes.

Manufacturing scale-up and supply chain management present additional operational risks.

Competitive Landscape

Innovent competes with leading Chinese biotech companies like BeiGene and Junshi Biosciences domestically, while facing global competition from established pharmaceutical giants in oncology and immunology. The company differentiates itself through its comprehensive platform, commercial execution in China, and strategic partnerships.

Publications

Patents

Pipeline

229